Celldex Therapeutics, Inc. (CLDX) Expected to Announce Earnings of -$0.23 Per Share

Equities analysts expect that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will report earnings of ($0.23) per share for the current quarter, according to Zacks. Two analysts have made estimates for Celldex Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.19). Celldex Therapeutics posted earnings of ($0.30) per share during the same quarter last year, which would suggest a positive year over year growth rate of 23.3%. The business is scheduled to report its next earnings results on Tuesday, March 13th.

On average, analysts expect that Celldex Therapeutics will report full year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($1.06) to ($0.86). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.90) per share, with EPS estimates ranging from ($1.09) to ($0.59). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Celldex Therapeutics.

CLDX has been the subject of a number of recent research reports. WBB Securities reissued a “buy” rating and issued a $10.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. HC Wainwright reissued a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. Finally, BidaskClub cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Three analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Celldex Therapeutics presently has an average rating of “Hold” and a consensus price target of $7.05.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in Celldex Therapeutics by 2.9% during the fourth quarter. BlackRock Inc. now owns 9,930,701 shares of the biopharmaceutical company’s stock worth $28,203,000 after purchasing an additional 279,287 shares during the period. Vanguard Group Inc. lifted its position in Celldex Therapeutics by 7.8% during the second quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after purchasing an additional 708,095 shares during the period. Meditor Group Ltd lifted its position in Celldex Therapeutics by 8.8% during the third quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock worth $18,054,000 after purchasing an additional 512,700 shares during the period. Northern Trust Corp lifted its position in Celldex Therapeutics by 12.2% during the second quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after purchasing an additional 219,661 shares during the period. Finally, Geode Capital Management LLC lifted its position in Celldex Therapeutics by 15.5% during the fourth quarter. Geode Capital Management LLC now owns 1,105,741 shares of the biopharmaceutical company’s stock worth $3,140,000 after purchasing an additional 148,077 shares during the period. 52.14% of the stock is owned by institutional investors and hedge funds.

Shares of Celldex Therapeutics (NASDAQ CLDX) traded down $0.03 during trading on Tuesday, hitting $2.32. 1,116,660 shares of the stock were exchanged, compared to its average volume of 1,215,405. The company has a market capitalization of $315.49, a PE ratio of -2.30 and a beta of 2.57. Celldex Therapeutics has a 52 week low of $2.20 and a 52 week high of $3.94.

TRADEMARK VIOLATION NOTICE: “Celldex Therapeutics, Inc. (CLDX) Expected to Announce Earnings of -$0.23 Per Share” was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/13/celldex-therapeutics-inc-cldx-expected-to-announce-earnings-of-0-23-per-share.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply